Abstract: An organic electric element includes a hole transport band layer which includes compound represented by Formula 1 and an electron transport band layer includes compound represented by Formula 2. The driving voltage of an organic electric element including the organic electric element can be lowered and the luminous efficiency and lifespan can be improved.

Abstract: A multilayer electronic component includes: a body having a dielectric layer and first and second internal electrodes alternately disposed with each other while having the dielectric layer interposed therebetween in a first direction; and an external electrode including a connection portion and a band portion extending from the connection portion onto first and second surfaces of the body, wherein the external electrode further includes an electrode layer connected to one of the first and second internal electrodes, a resin layer in contact with the first and second surfaces, and a conductive resin layer disposed on the electrode layer and extending to the resin layer, and L1??L1 when L1 indicates a second-directional size of the resin layer in the band portion, and L1? indicates a second-directional size of the conductive resin layer in the band portion.

Abstract: A display device includes a base layer having a plurality of pixel regions and a non-pixel region surrounding the plurality of pixel regions, a circuit layer including a plurality of insulating layers and a plurality of conductive patterns, a light-emitting element layer, and an input sensing unit including a sensing pattern overlapping the non-pixel region. The light-emitting element layer includes a pixel defining structure overlapping the non-pixel region, and a plurality of light-emitting elements. The pixel defining structure includes a step pattern surrounding a portion of each of the plurality of pixel regions. The plurality of conductive patterns include a shielding pattern on the plurality of insulating layers and overlapping at the step pattern in a plan view, at least a portion of the shielding pattern being applied with voltage.

Abstract: The present invention relates to a system for diagnosis and management of indoor air quality, and more particularly to a system for diagnosis and management of indoor air quality which is capable of obtaining and analyzing air quality data by measuring the indoor air quality of a vehicle or accommodation space and of detecting smoking or non-smoking, the type of smoking, and an abnormal situation by diagnosing at least one of indoor smoking and smoking types. In addition, the present invention relates to a technology for facilitating the management of accommodation by efficiently diagnosing indoor air quality.

Abstract: A method of manufacturing a display device includes providing an adhesive material layer on a display panel, curing the adhesive material layer to form an adhesive layer, providing a cover layer on the adhesive layer, and adhering the cover layer to the adhesive layer, and a modulus of the adhesive layer at room temperature is in a range of about 103 Pa to about 106 Pa.

Abstract: In a backlight apparatus, a master driving circuit generates a transmission frame including a training period including a clock training pattern and a data period including a plurality of data packets respectively corresponding to the plurality of blocks. A plurality of slave driving circuits correspond to the plurality of blocks, respectively, and are connected to the master driving circuit in a daisy chain structure. Each slave driving circuit receives the transmission frame through the daisy chain structure, recovers a clock based on the clock training pattern, and drives the plurality of light emitting elements included in a corresponding block among the plurality of blocks based on its own data packet among a plurality of data packets.

Abstract: The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, a pharmaceutical use thereof, and a method for preparing the same. According to the present invention, the novel compounds, optical isomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; internal secretion; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, and chromosomal aberration.

Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.

Abstract: There are provided a display device and a method of fabricating a display device. The display device includes: a substrate including a first surface and a second surface opposite to the first surface; a display element layer disposed on the first surface of the substrate, and a panel bottom member disposed on the second surface of the substrate. The panel bottom member includes: a light-blocking layer including a first base resin and light-blocking particles dispersed in the first base resin; a buffer layer including a second base resin; and a thermal protection member including a thermal protection material. A profile of the light-blocking layer conforms to a profile of the buffer layer in a plan view, and a surface of the light-blocking layer and a surface of the buffer layer are in direct contact with each other.

Abstract: Provided is a novel branched poly(3-hydroxypropionic acid)polymer.

Abstract: Provided is a novel a copolymer with structures including a branched poly(3-hydroxypropionic acid) and a poly(lactic acid).

Abstract: An electronic apparatus including a display unit having a signal transmission region, an active region surrounding at least a portion of the signal transmission region, and a peripheral region adjacent to the active region, and an input sensor including sensing electrodes each having a plurality of sensing electrode patterns which overlap the active region and a sensing circuit having a sensing pattern overlapping the signal transmission region and a sensing line connected to the sensing pattern, and on the display unit, wherein a hole passing through the display unit and the input sensor is defined to correspond to the signal transmission region, and in a plan view, a portion of the sensing pattern either overlaps the floating pattern or is between the sensing electrode patterns and the floating pattern, and the other portion of the sensing pattern is between the floating pattern and the hole.

Abstract: This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is —CH2CH?C(CH3)2, R2 is methyl, R3 is CsHn, R4 is —C(O)N(R4a)(R4b), R5 is H, R6 is OH, and R7 is H. Compounds of the present disclosure were tested in agonist and antagonist mode for both the CB1 and CB2 receptors. The tested compounds were generally found to exhibit activity in antagonist mode at the CB1 and CB2 receptor.

Abstract: The present disclosure is directed to compounds of formula (I): wherein R1, R2, R3, R3a, R4, Y, and X are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: The present disclosure is directed to compounds of formula (I): wherein X, Y, Z, R1, R2a, R2b, R3, and L are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: The present disclosure is directed to compounds of formula (1): wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.

Abstract: This disclosure relates generally to cannabinoid derivatives having the formula (I), wherein R4 is hydrogen, —C(Q1)N(R4a)(R4b) or —C(R4J)(R4k)N(R4e)C(0)R4f, R6 is hydrogen, —C(Q2)N(R6a)(R6b) or —C(R6J)(R6k)N(R6e)C(0)R6f, provided that R6 is not hydrogen when R4 is hydrogen. Pharmaceutical compositions for the prevention or treatment of a disease associated with a cannabinoid receptor (such as CB1 or CB2) in a subject in need thereof, and methods of using the cannabinoid derivatives are also described.

Abstract: The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Abstract: The present invention relates to a cosmetic composition for wrinkle reduction comprising, as an active ingredient, a Gynostemma pentaphyllum gypenoside fraction and, more specifically, to a cosmetic composition for wrinkle reduction, wherein the Gynostemma pentaphyllum gypenoside fraction includes at least one gypenoside selected from the group consisting of gypenoside UL1, gypenoside UL2, gypenoside UL3, gypenoside UL4, gypenoside UL5, gypenoside UL6, and gypenoside UL7.